JAK-STAT pathway heterogeneity governs immunotherapy response in breast cancer
The JAK-STAT pathway (JSP) is a well-known oncogenic cascade; however, recent clinical trials have detected JSP upregulation in breast cancer following anti-PD-1 immunotherapy.